Loading…
Science Corporation reports an initial Stargardt-disease use of PRIMA, an early clinical milestone whose therapeutic significance remains unproven.
Limits of the evidence: The report relays the company's account of one patient and early rehabilitation sessions; no independent clinical results or trial data are provided.
What to watch
Assessment revised Oct 14, 2026
Science Corporation implants its vision-restoring chip in its first Stargardt disease patient
TechCrunch AIOct 13, 2026First report
First assessment, from TechCrunch AI
No maturity ladder applies to this desk.
Sens.ai aggregates and assesses published reporting. The assessment above is machine generated; the original sources are authoritative.